Adaptive Biotechnologies Corp
NASDAQ:ADPT

Watchlist Manager
Adaptive Biotechnologies Corp Logo
Adaptive Biotechnologies Corp
NASDAQ:ADPT
Watchlist
Price: 4.69 USD 7.32% Market Closed
Market Cap: 692.2m USD
Have any thoughts about
Adaptive Biotechnologies Corp?
Write Note

Intrinsic Value

ADPT's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one ADPT stock under the Base Case scenario is 6.89 USD. Compared to the current market price of 4.69 USD, Adaptive Biotechnologies Corp is Undervalued by 32%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

ADPT Intrinsic Value
6.89 USD
Undervaluation 32%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Adaptive Biotechnologies Corp

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for ADPT cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about ADPT?
Bearish
Neutral
Bullish

Fundamental Analysis

Economic Moat
Adaptive Biotechnologies Corp

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Adaptive Biotechnologies Corp

Provide an overview of the primary business activities
of Adaptive Biotechnologies Corp.

What unique competitive advantages
does Adaptive Biotechnologies Corp hold over its rivals?

What risks and challenges
does Adaptive Biotechnologies Corp face in the near future?

Has there been any significant insider trading activity
in Adaptive Biotechnologies Corp recently?

Summarize the latest earnings call
of Adaptive Biotechnologies Corp.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Adaptive Biotechnologies Corp.

Provide P/S
for Adaptive Biotechnologies Corp.

Provide P/E
for Adaptive Biotechnologies Corp.

Provide P/OCF
for Adaptive Biotechnologies Corp.

Provide P/FCFE
for Adaptive Biotechnologies Corp.

Provide P/B
for Adaptive Biotechnologies Corp.

Provide EV/S
for Adaptive Biotechnologies Corp.

Provide EV/GP
for Adaptive Biotechnologies Corp.

Provide EV/EBITDA
for Adaptive Biotechnologies Corp.

Provide EV/EBIT
for Adaptive Biotechnologies Corp.

Provide EV/OCF
for Adaptive Biotechnologies Corp.

Provide EV/FCFF
for Adaptive Biotechnologies Corp.

Provide EV/IC
for Adaptive Biotechnologies Corp.

Show me price targets
for Adaptive Biotechnologies Corp made by professional analysts.

What are the Revenue projections
for Adaptive Biotechnologies Corp?

How accurate were the past Revenue estimates
for Adaptive Biotechnologies Corp?

What are the Net Income projections
for Adaptive Biotechnologies Corp?

How accurate were the past Net Income estimates
for Adaptive Biotechnologies Corp?

What are the EPS projections
for Adaptive Biotechnologies Corp?

How accurate were the past EPS estimates
for Adaptive Biotechnologies Corp?

What are the EBIT projections
for Adaptive Biotechnologies Corp?

How accurate were the past EBIT estimates
for Adaptive Biotechnologies Corp?

Compare the revenue forecasts
for Adaptive Biotechnologies Corp with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Adaptive Biotechnologies Corp and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Adaptive Biotechnologies Corp against its competitors.

Analyze the profit margins
(gross, operating, and net) of Adaptive Biotechnologies Corp compared to its peers.

Compare the P/E ratios
of Adaptive Biotechnologies Corp against its peers.

Discuss the investment returns and shareholder value creation
comparing Adaptive Biotechnologies Corp with its peers.

Analyze the financial leverage
of Adaptive Biotechnologies Corp compared to its main competitors.

Show all profitability ratios
for Adaptive Biotechnologies Corp.

Provide ROE
for Adaptive Biotechnologies Corp.

Provide ROA
for Adaptive Biotechnologies Corp.

Provide ROIC
for Adaptive Biotechnologies Corp.

Provide ROCE
for Adaptive Biotechnologies Corp.

Provide Gross Margin
for Adaptive Biotechnologies Corp.

Provide Operating Margin
for Adaptive Biotechnologies Corp.

Provide Net Margin
for Adaptive Biotechnologies Corp.

Provide FCF Margin
for Adaptive Biotechnologies Corp.

Show all solvency ratios
for Adaptive Biotechnologies Corp.

Provide D/E Ratio
for Adaptive Biotechnologies Corp.

Provide D/A Ratio
for Adaptive Biotechnologies Corp.

Provide Interest Coverage Ratio
for Adaptive Biotechnologies Corp.

Provide Altman Z-Score Ratio
for Adaptive Biotechnologies Corp.

Provide Quick Ratio
for Adaptive Biotechnologies Corp.

Provide Current Ratio
for Adaptive Biotechnologies Corp.

Provide Cash Ratio
for Adaptive Biotechnologies Corp.

What is the historical Revenue growth
over the last 5 years for Adaptive Biotechnologies Corp?

What is the historical Net Income growth
over the last 5 years for Adaptive Biotechnologies Corp?

What is the current Free Cash Flow
of Adaptive Biotechnologies Corp?

Discuss the annual earnings per share (EPS)
trend over the past five years for Adaptive Biotechnologies Corp.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Adaptive Biotechnologies Corp

Current Assets 308.3m
Cash & Short-Term Investments 243.3m
Receivables 40.8m
Other Current Assets 24.2m
Non-Current Assets 250.2m
Long-Term Investments 23.9m
PP&E 97.8m
Intangibles 122.8m
Other Non-Current Assets 5.6m
Current Liabilities 87.6m
Accounts Payable 7.4m
Accrued Liabilities 28.4m
Other Current Liabilities 51.9m
Non-Current Liabilities 247.1m
Long-Term Debt 132.7m
Other Non-Current Liabilities 114.4m
Efficiency

Earnings Waterfall
Adaptive Biotechnologies Corp

Revenue
177.3m USD
Cost of Revenue
-73.7m USD
Gross Profit
103.6m USD
Operating Expenses
-270.8m USD
Operating Income
-167.1m USD
Other Expenses
-28.1m USD
Net Income
-195.2m USD

Free Cash Flow Analysis
Adaptive Biotechnologies Corp

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

ADPT Profitability Score
Profitability Due Diligence

Adaptive Biotechnologies Corp's profitability score is 23/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Positive Revenue Growth Forecast
Positive 3-Years Revenue Growth
Negative 1-Year Revenue Growth
23/100
Profitability
Score

Adaptive Biotechnologies Corp's profitability score is 23/100. The higher the profitability score, the more profitable the company is.

ADPT Solvency Score
Solvency Due Diligence

Adaptive Biotechnologies Corp's solvency score is 41/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Low D/E
Negative Net Debt
Long-Term Solvency
41/100
Solvency
Score

Adaptive Biotechnologies Corp's solvency score is 41/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

ADPT Price Targets Summary
Adaptive Biotechnologies Corp

Wall Street analysts forecast ADPT stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ADPT is 7.57 USD with a low forecast of 5.56 USD and a high forecast of 10.5 USD.

Lowest
Price Target
5.56 USD
18% Upside
Average
Price Target
7.57 USD
61% Upside
Highest
Price Target
10.5 USD
124% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for ADPT?

Click here to dive deeper.

Dividends

Adaptive Biotechnologies Corp
does not pay dividends
Shareholder Yield

Current shareholder yield for ADPT is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

ADPT Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

ADPT News

Other Videos

Profile

Adaptive Biotechnologies Corp Logo
Adaptive Biotechnologies Corp

Country

United States of America

Industry

Life Sciences Tools & Services

Market Cap

692.1m USD

Dividend Yield

0%

Description

Adaptive Biotechnologies Corp. engages in the development of an immune medicine platform. The company is headquartered in Seattle, Washington and currently employs 858 full-time employees. The company went IPO on 2019-06-27. The firm is focused on using the biology of the adaptive immune system to develop the diagnosis and treatment of disease. Its immune medicine platform combines a suite of chemistry, biology and machine learning to generate clinical immunomics data to decode the adaptive immune system. Its commercial research products include immunoSEQ and immunoSEQ T-MAP. immunoSEQ utilizes bias-controlled polymerase chain reaction (PCR) to sequence immune receptors from deoxyribonucleic (DNA). Its clonoSEQ diagnostic test detects and monitors the number of cancer cells that are present in a patient’s body during and after treatment, known as minimal residual disease (MRD). The company uses its T cell receptor (TCR)-Antigen Map to develop research solutions and diagnostic products, such as immunoSEQ T-MAP and T-Detect. The company also focuses on developing immune-mediated therapies in oncology and other disease areas.

Contact

WASHINGTON
Seattle
1165 Eastlake Ave E
+12066590067.0
www.adaptivebiotech.com

IPO

2019-06-27

Employees

858

Officers

Co-Founder, CEO & Chairman
Mr. Chad M. Robins M.B.A.
President & COO
Ms. Julie Rubinstein
Co-Founder & Chief Scientific Officer
Dr. Harlan S. Robins Ph.D.
Chief Commercial Officer of Immune Medicine
Dr. Sharon Benzeno Ph.D.
Founder
Mr. Christopher Carlson Ph.D.
VP, CFO & Principal Accounting Officer
Mr. Kyle Piskel
Show More
Vice President of Investor Relations
Karina Calzadilla
Senior VP, General Counsel & Corporate Secretary
Ms. Stacy L. Taylor
Chief People Officer
Mr. Francis T. Lo
Chief Commercial Officer of MRD
Ms. Susan Bobulsky
Show Less

See Also

Discover More
What is the Intrinsic Value of one ADPT stock?

The intrinsic value of one ADPT stock under the Base Case scenario is 6.89 USD.

Is ADPT stock undervalued or overvalued?

Compared to the current market price of 4.69 USD, Adaptive Biotechnologies Corp is Undervalued by 32%.

Back to Top